Isatuximab-carfilzomib-dexamethasone Immediately after Failing of the Quadruplet Daratumumab-bortezomib-lenalidomide-dexamethasone (Dara-Vrd): Striking Response with No Washout in a Newly Diagnosed Multiple Myeloma
Clinical case reports（2024）
Abstract
Biochemical evolution of serum IgG-Kappa monoclonal component during the first line with VRD (x1), DARA-VRD (x4), and the second line with ISA-KD (x4).
MoreTranslated text
Key words
daratumumab-refractory myeloma,first-line therapy,isatuximab post daratumumab,newly diagnosed multiple myeloma
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined